NewsSource: EClinCloud

EClinCloud Product Overview | RTSM · Randomization and Trial Supply Management System

2 min readEClinCloud Editorial Team
EClinCloud Product Overview | RTSM · Randomization and Trial Supply Management System news header image

Source: EClinCloud. Author: EClinCloud.


The EClinCloud RTSM (Randomization and Trial Supply Management) system is an advanced, web-based randomization and drug supply management platform for multicenter clinical trials. Designed with a risk-based approach and integrated with AI, it efficiently manages large-scale, multicenter clinical trials running multiple protocols in parallel, helping investigators execute diverse study designs, including complex randomization schemes and trial designs. Through the EClinCloud platform, investigators can control trial workflows more precisely, ensure smooth trial conduct, and improve drug management and utilization.


computer-ai.png

AI-Driven One-Stop Product + Service Solution


🔍 What Does EClinCloud Offer?

◉ RTSM system

◉ System configuration services

◉ Randomization and blinding services

◉ Drug supply management services



💻 EClinCloud RTSM System Features




◉ Preconfigured with multiple randomization algorithms and blinding maintenance settings to support multi-cohort and complex protocol designs

◉ Uses a flexible combination treatment regimen design module to support both multi-protocol management and dynamic-factor dosing

◉ Provides granular management across the entire trial lifecycle for participant randomization, dosing, and blinding maintenance

◉ Integrates with depot and logistics operations and provides AI-driven drug supply planning and alert notifications to improve drug utilization



💡 Why Choose EClinCloud RTSM?


❖ Clean interface and clear workflows that adapt to changing protocol requirements and improve efficiency

❖ High system adaptability and flexibility, enabling seamless integration with different systems and data interoperability

❖ Full drug lifecycle management and intelligent alerts to control risks, delivering a comprehensive solution for clinical trial drug management

❖ Automated and standardized workflows enhance the authenticity and credibility of study data, providing solid support for clinical research






About EClinCloud


EClinCloud is a leading AI company in the clinical research industry, building an integrated intelligent clinical cloud platform and endpoint assessment technologies powered by AI. It provides global pharmaceutical companies and research institutions with technology products—including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM—as well as scale management, linguistic validation, rater training, and data quality analysis services to deliver efficient, precise digital solutions. Leveraging AI predictive models and an intelligent data platform, it dynamically assesses and helps improve drug clinical trial success rates, helping shorten drug and medical device R&D cycles to benefit patients.







Article illustration





Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.